Israeli professor helps US PTSD research
Dr. Yair Bar-Haim, of Tel Aviv University is performing his Attention Bias Modification treatment at Creighton and Nebraska Universities in Omaha. The treatment hopes to help US soldiers suffering from Post Traumatic Stress Disorder, following service in Iraq and Afghanistan.
Immunity research requires the Midas touch
(Thanks to Israel21c) Tel Aviv University scientists have developed a new method of prompting the immune system to create protective antibodies. Using nano-particles made of pure gold, the immune system responds when they are coated with different chemical residues.
Scientists search for the Peres gene
Galilee Genetics Analysis (GGA) Laboratories in the Golan has taken a sample of DNA from the saliva of Israeli President Shimon Peres to try to find out the secret of his longevity and mental clarity.
Let’s collaborate
A new open-access online medical journal seeks to promote intellectual interactions between scholars in Israel and abroad. All work on the journal (including editing and peer reviews) is voluntary and unpaid. It will deal with all aspects of health care and aims to help develop health policy globally.
One drop of blood can save your life
Professor Andrew Levy of the Israel Technion describes the test that can discover which diabetics are also susceptible to heart disease. He also developed treatment using Vitamin E that has a dramatic effect on survival times for affected individuals.
A 90-year old innovator
20 years after his retirement, Hebrew University emeritus Professor Nathan Citri developed a novel kit enabling speedy detection of multi-drug and extremely antibiotics-resistant “superbugs”.
Orthodox Jewish women age slower
Researchers at Hadassah University Hospital have discovered that four genes generate an anti-aging effect on women who conceive naturally after age 45. The findings were the result of a genetic study of ultra-Orthodox Ashkenazi women from Mea She'arim who have at least six children.
Israeli drug can save sight
Israel’s Can-Fite BioPharma has reported successful pre-clinical trials of CF101 for the treatment of anterior uveitis – the inflammation of the iris. An earlier trial found CF101 effective in treating posterior uveitis – inflammation of the retina. Uveitis is a common cause of blindness in the USA.
A very smart delivery platform
Ben Gurion University’s V-Smart drug delivery technology has been licensed to a New York biotechnology company. Lauren Sciences will develop the technology for treating Parkinson's, Alzheimer's, Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig’s), and brain malignancies.